{"id":49916,"date":"2022-10-21T16:02:08","date_gmt":"2022-10-21T14:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wegovy-semaglutide-drug-insight-and-market-forecast-report-to-2032-researchandmarkets-com\/"},"modified":"2022-10-21T16:02:08","modified_gmt":"2022-10-21T14:02:08","slug":"wegovy-semaglutide-drug-insight-and-market-forecast-report-to-2032-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wegovy-semaglutide-drug-insight-and-market-forecast-report-to-2032-researchandmarkets-com\/","title":{"rendered":"WEGOVY (Semaglutide) Drug Insight and Market Forecast Report to 2032 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “WEGOVY (Semaglutide), Drug Insight and Market Forecast – 2032”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report provides comprehensive insights about WEGOVY (Semaglutide) for Obesity in the 7MM. A detailed picture of the WEGOVY (Semaglutide) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the WEGOVY (Semaglutide) for Obesity.\n<\/p>\n

\nThe report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the WEGOVY (Semaglutide) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.\n<\/p>\n

\nDrug Summary<\/strong>\n<\/p>\n

\nWEGOVY (Semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. The 2.4 mg injection is an injectable prescription medicine used for adults with obesity (BMI \u226530) or overweight (excess weight) (BMI \u226527) who also have weight-related medical problems to help them lose weight and keep the weight off.\n<\/p>\n

\nWEGOVY should be taken once a week, on the same day each week, at any time of day, with or without meals. Inject subcutaneously into the abdomen, thigh, or upper arm. Begin with 0.25 mg once a week for four weeks. Increase the dose every four weeks until it reaches 2.4 mg. WEGOVY’s maintenance dose is 2.4 mg once weekly.\n<\/p>\n

\nSemaglutide is a GLP-1 analog with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. According to animal studies, semaglutide is distributed to and activates neurons in brain regions involved in food intake regulation.\n<\/p>\n

\nScope of the Report<\/strong>\n<\/p>\n

\nThe report provides insights into:<\/strong>\n<\/p>\n